Loading...
XKRX
048410
Market cap498mUSD
Oct 08, Last price  
6,930.00KRW
1D
-4.94%
1Q
-4.55%
Jan 2017
30.75%
IPO
-40.26%
Name

Hyundai Bioscience Co Ltd

Chart & performance

D1W1MN
XKRX:048410 chart
P/E
—
P/S
190.13
EPS
—
Div yield, %
—
Shrs. gr., 5y
4.71%
Rev. gr., 5y
-22.41%
Revenues
3.52b
-76.63%
228,826,120,000117,172,745,000118,874,679,00093,926,922,00086,340,207,00047,653,385,55037,079,378,00025,538,238,61028,912,613,04040,674,617,76736,101,390,00031,970,193,00031,235,880,00030,085,994,56212,511,416,0009,241,494,0007,851,578,1079,481,385,00015,050,025,0003,517,369,000
Net income
-22.13b
L+219.33%
-98,567,686,0001,907,157,0005,257,555,000-14,464,895,000-7,942,975,000-16,936,663,000-7,957,931,000-10,352,199,736-3,108,598,190711,285,387-8,070,237,0001,218,194,0002,617,921,000767,215,168-8,259,902,000-20,051,087,000-15,807,267,634-14,499,358,000-6,929,528,000-22,128,348,000
CFO
-17.39b
L
-12,726,369,000-24,958,819,0006,115,601,000-4,154,617,000-7,394,078,5153,969,577,000-7,870,647,000-9,177,527,770-302,743,80087,362,580-4,338,360,000-4,181,286,0005,005,280,0008,897,522,0007,501,969,000-538,477,000-16,543,514,000-6,008,318,9202,257,054,000-17,394,295,000
Dividend
Dec 29, 20031.432 KRW/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Hyundai Bioscience Co., Ltd. is a biotechnology firm dedicated to creating and commercializing bio-fusion technologies that enable the precise delivery of active compounds throughout the human anatomy. The company offers Vitabrid C12, a novel vitamin C product engineered to provide active vitamin C directly to the skin. Additionally, it is advancing organic-inorganic hybrid technology, which functions as a sophisticated drug delivery system. This system integrates bio-friendly minerals to ensure the targeted and efficient transport of active substances to specific sites, a capability also leveraged in its anticancer drug carrier innovations. The enterprise was established in 2000 and is headquartered in Seoul, South Korea.

Key people

Yeong Gwon Jung
President · since 2025
Sang Gi Oh
Chief Executive Officer, Director · since 2013
Taek Seong Kim
Vice President, Director
Gwang Hui Kim
Managing Director
Yong Ho Cho
Internal Auditor
Dong Su Choi
Assistant Managing Director · since 2024
Geun Wu Jin
Director
Jin Hwan Jung
Director · since 2025
Gyeong Yil Kim
Director · since 2022
Jae Mun Bae
Non-Executive Independent Director
Jin Seok Kim
Non-Executive Independent Director · since 2023
Jong Seon Park
Non-Executive Independent Director
URL
http://www.hyundaibioscience.com/
IPO date
Aug 08, 2002
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT